Subscribe

News
Video
Podcasts
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Opinion|Videos|August 19, 2024

Key Takeaways on Enhancing Outcomes for mNSCLC Without Targetable Driver Mutations

Author(s)Mark Socinski, MD, John Heymach, MD, PhD, Wade Iams, MD

The panel provides insights on enhancing outcomes for patients with metastatic non-small cell lung cancer without targetable driver mutations.

Episodes in this series

EP. 1 Biomarker Testing and Guideline-Recommended Care in mNSCLC

EP. 1 Biomarker Testing and Guideline-Recommended Care in mNSCLC

EP. 2 Strategies to Increase Biomarker Testing Rates

EP. 2 Strategies to Increase Biomarker Testing Rates

EP. 3 Limitations on Optimal Biomarker Testing Rates

EP. 3 Limitations on Optimal Biomarker Testing Rates

EP. 4 Impact of Biomarker Testing on Treatment Selection and Outcomes

EP. 4 Impact of Biomarker Testing on Treatment Selection and Outcomes

EP. 5 Key Challenges and Unmet Needs in Newly Diagnosed Driver-Negative mNSCLC

EP. 5 Key Challenges and Unmet Needs in Newly Diagnosed Driver-Negative mNSCLC

EP. 6 NCCN Recommendations by PD-L1 Expression Level

EP. 6 NCCN Recommendations by PD-L1 Expression Level

EP. 7 Limitations of NCCN PD-L1 Expression Recommendations

EP. 7 Limitations of NCCN PD-L1 Expression Recommendations

EP. 8 Emerging Data and Evidence for Dual Immunotherapy plus Chemotherapy in First-Line mNSCLC

EP. 8 Emerging Data and Evidence for Dual Immunotherapy plus Chemotherapy in First-Line mNSCLC

EP. 9 Genetic Alterations Impacting Treatment Response and Biomarker Testing Rates in mNSCLC

EP. 9 Genetic Alterations Impacting Treatment Response and Biomarker Testing Rates in mNSCLC

EP. 10 Molecular Characteristics Beyond Mutations Influencing Immunotherapy Response

EP. 10 Molecular Characteristics Beyond Mutations Influencing Immunotherapy Response

A panel of 4 experts on lung cancer

EP. 11 Clinical Factors Impacting Immunotherapy Response and Optimizing Patient Selection

A panel of 4 experts on lung cancer

EP. 12 Overcoming Immunotherapy Resistance: Identifying Non-Responders and Novel Approaches

A panel of 4 experts on lung cancer

EP. 13 Key Takeaways on Enhancing Outcomes for mNSCLC Without Targetable Driver Mutations

Video content above is prompted by the following:

Looking ahead, what is the most critical priority to meaningfully enhance outcomes for patients with metastatic non-small cell lung cancer without targetable driver mutations?

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Female doctor checking woman's lymph nodes | Image Credit: Syda Productions - stock.adobe.com

3+1 Lymph Node Sampling Not Associated With Increased Postoperative Complications in NSCLC

ByBrooke McCormick

June 10th 2026

Diversity | Image Credit: freshidea - stock.adobe.com

Black-White NSCLC Survival Gap Widens in Counties With Greater Racial Inequity

ByBrooke McCormick

June 4th 2026

Jessica Paulus, ScD | Image: LinkedIn

Ontada Research Shows Relationship Between NCCN Distress Thermometer Scores and OS in Common Cancers

May 26th 2026

Dr Deborah Doroshow

Clinical Trial Education, Treatment Access Central to Improving Lung Cancer Care: Deborah Doroshow, MD, PhD

ByBrooke McCormick,Deborah Doroshow, MD, PhD,Pearl Steinzor

May 13th 2026

Dr Deborah Doroshow

Equitable Access Remains a Major Unmet Need in Lung Cancer Care: Deborah Doroshow, MD, PhD

ByBrooke McCormick,Deborah Doroshow, MD, PhD,Pearl Steinzor

May 12th 2026

Trending on AJMC

EHA 2026 Late Breakers Deliver Practice-Shifting Phase 3 Data and Novel CAR T Approaches Across Hematology

Paul Richardson, MD, Calls Mezigdomide “CAR T in a Pill” for Patients With R/R Multiple Myeloma

MRD-Guided CLL Treatment Duration: Personalization or Malpractice?

SENTRY Trial Shows Survival, Spleen Benefits in Myelofibrosis: Claire Harrison, MD

Teclistamab Outperforms Len/Dex in High-Risk Smoldering Myeloma With Higher CR Rate, PFS: Omar Nadeem, MD